Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

BACKGROUND The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality. We tested the hypothesis that this benefit was partially due to improvement in endothelial function and/or to amplified suppression of the vascular renin-angiotensin axis. METHODS AND RESULTS We performed a randomized, placebo-controlled, double-blind crossover study on 10 patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy, comparing 50 mg/d spironolactone (1 month) versus placebo. Forearm vasculature endothelial function was assessed by bilateral forearm venous occlusion plethysmography using acetylcholine and N-monomethyl-L-arginine (L-NMMA), with sodium nitroprusside as a control vasodilator. Also, vascular ACE activity was assessed by use of angiotensin (Ang) I, with Ang II as a control vasoconstrictor. Spironolactone significantly increased the forearm blood flow response to acetylcholine (percentage change in forearm blood flow [mean+/-SEM], 177+/-29% versus 95+/-20%, spironolactone versus placebo; P<0.001), with an associated increase in vasoconstriction due to L-NMMA (-35+/-6% versus -18+/-4%; P<0.05). The Ang I response was also significantly reduced with spironolactone (P<0.05), with Ang II responses unaltered. CONCLUSIONS Spironolactone improves endothelial dysfunction, increases NO bioactivity, and inhibits vascular Ang I/Ang II conversion in patients with heart failure, providing novel mechanisms for its beneficial effect on cardiovascular mortality.

[1]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[2]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[3]  A. Struthers.  Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? , 1999, British journal of clinical pharmacology.

[4]  A. Struthers,et al.  Nitric Oxide Regulates Renin Release During Salt Depletion but Does Not Alter Angiotensin Responses in Normal Humans , 1999, Journal of cardiovascular pharmacology and therapeutics.

[5]  H. Drexler.  Endothelium as a therapeutic target in heart failure. , 1998, Circulation.

[6]  C. Garland,et al.  K+ is an endothelium-derived hyperpolarizing factor in rat arteries , 1998, Nature.

[7]  J. Cohn,et al.  Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. , 1998, European heart journal.

[8]  A. Struthers,et al.  C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. , 1995, Circulation.

[9]  U. Ikeda,et al.  Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. , 1995, European journal of pharmacology.

[10]  P Vallance,et al.  Measuring forearm blood flow and interpreting the responses to drugs and mediators. , 1995, Hypertension.

[11]  K. Weber,et al.  Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. , 1993, The Journal of laboratory and clinical medicine.

[12]  K. Weber,et al.  Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. , 1993, The Journal of laboratory and clinical medicine.

[13]  S. Linas,et al.  Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. , 1992, Hypertension.

[14]  H. Eichler,et al.  Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. , 1987, Circulation.